Beta Drugs Balance Sheet Health
Financial Health criteria checks 6/6
Beta Drugs has a total shareholder equity of ₹1.8B and total debt of ₹190.6M, which brings its debt-to-equity ratio to 10.5%. Its total assets and total liabilities are ₹2.9B and ₹1.1B respectively. Beta Drugs's EBIT is ₹558.1M making its interest coverage ratio 27.2. It has cash and short-term investments of ₹278.9M.
Key information
10.5%
Debt to equity ratio
₹190.60m
Debt
| Interest coverage ratio | 27.2x |
| Cash | ₹278.87m |
| Equity | ₹1.81b |
| Total liabilities | ₹1.14b |
| Total assets | ₹2.95b |
Recent financial health updates
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Financial Position Analysis
Short Term Liabilities: BETA's short term assets (₹2.1B) exceed its short term liabilities (₹972.5M).
Long Term Liabilities: BETA's short term assets (₹2.1B) exceed its long term liabilities (₹164.0M).
Debt to Equity History and Analysis
Debt Level: BETA has more cash than its total debt.
Reducing Debt: BETA's debt to equity ratio has reduced from 32.5% to 10.5% over the past 5 years.
Debt Coverage: BETA's debt is well covered by operating cash flow (132.1%).
Interest Coverage: BETA's interest payments on its debt are well covered by EBIT (27.2x coverage).